## **Product** Data Sheet

## Nifuroxazide-d4

**Cat. No.:** HY-B1436S **CAS No.:** 1188487-83-3

 $\begin{tabular}{ll} \begin{tabular}{ll} \be$ 

Molecular Weight: 279.24

Target: STAT; Bacterial; Antibiotic

Pathway: JAK/STAT Signaling; Stem Cell/Wnt; Anti-infection

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

## **BIOLOGICAL ACTIVITY**

Description	Nifuroxazide-d4 is the deuterium labeled Nifuroxazide. Nifuroxazide is an effective inhibitor of STAT3, also exerts potent anti-tumor and anti-metastasis activity.
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## **REFERENCES**

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

[2]. Nelson EA, et al. Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. Blood. 2008 Dec 15;112(13):5095-102.

 $[3]. \ Zhu\ Y, et\ al.\ Nifuroxazide\ exerts\ potent\ anti-tumor\ and\ anti-metastasis\ activity\ in\ melanoma.\ Sci\ Rep.\ 2016\ Feb\ 2;6:20253.$ 

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA